ADARx Pharmaceuticals, Inc. Common Stock (ADRX) - Total Liabilities
Based on the latest financial reports, ADARx Pharmaceuticals, Inc. Common Stock (ADRX) has total liabilities worth $707.38 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of ADARx Pharmaceuticals, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
ADARx Pharmaceuticals, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how ADARx Pharmaceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check ADARx Pharmaceuticals, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
ADARx Pharmaceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of ADARx Pharmaceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Daily Media Group Co Ltd
SHG:600633
|
China | CN¥1.69 Billion |
|
Galapagos NV ADR
NASDAQ:GLPG
|
USA | $119.06 Million |
|
EMEIS SA
PA:EMEIS
|
France | €11.25 Billion |
|
Central China Land Media Co Ltd
SHE:000719
|
China | CN¥7.07 Billion |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
China | CN¥32.38 Billion |
|
Karooooo Ltd
NASDAQ:KARO
|
USA | $2.66 Billion |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
USA | $1.66 Billion |
|
DRDGOLD Limited
JSE:DRD
|
South Africa | ZAC3.36 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down ADARx Pharmaceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ADARx Pharmaceuticals, Inc. Common Stock assets under control.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADARx Pharmaceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADARx Pharmaceuticals, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of ADARx Pharmaceuticals, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $709.91 Million | +91.56% |
| 2024-12-31 | $370.60 Million | -- |
About ADARx Pharmaceuticals, Inc. Common Stock
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple ind… Read more